top of page
News


Pyxis Partners uniquely positioned to help clinical trial sponsors meet new diversity mandate
Washington, DC (February 15, 2023) – Pyxis Partners, a Washington, DC based public affairs and social impact firm that advances health...


Chronic Houselessness in the United States
Health Outcomes, Care Delivery, and the Programs that Bridge the Gap Background In January 2022, around 127,768 individuals - nearly...


Pyxis Partners receives District of Columbia Certified Business Enterprise (CBE) Designation
Washington, DC (January 27, 2023) - Pyxis Partners, LLC, a Washington, DC-based public affairs and social impact firm that advances...


Statement on the Passage of the Respect for Marriage Act
Today the United States Congress upheld on a national level what we know to be a basic human right – to love and marry the person you...


Perspectives and Planning for the 118th Congress
The deep divide in American politics was on full display in the November elections both in numerous individual races and the resulting...


The Role of Healthcare Providers in the COVID-19 Response Moving Forward
Vaccine hesitancy has been a public health concern for years and with the emergence of the novel coronavirus, SARS-CoV-2, and quick...


Pyxis on Point: Expert Analysis and Preview of the 2022 Midterm Election Impact on Healthcare
As we head into the final stretch of the 2022 elections, our team at Pyxis Partners is offering insights on what to expect on election...


Policy Brief: Food Insecurity in the United States
Access to healthy food is vital to live, yet 13.5 million American households struggle with food insecurity. The lack of access to...


Policy Brief: Telehealth May Improve Access to Mental Health Services, but not Equity
During the height of the COVID-19 pandemic people experienced periods of isolation, uncertainty, and stress which contributed to an...


The Commonwealth Fund: The Accelerated Approval Pathway for New Drug Therapies
In June 2021, the Food and Drug Administration (FDA) approved the Alzheimer’s drug Aduhelm through the agency’s Accelerated Approval...
bottom of page